| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Clinical Chemistry (Dr. Bonifacio, V. Lampasona and S. Zanaboni), Neuroimmunology Unit, DIBIT, Department of Neuroscience (Drs. Furlan and Martino), and Department of Neurology and Neurophysiology (Drs. Fazio, Comi, and Martino), University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; and Laboratory of Neuroimmunology (Dr. Franciotta), IRCCS "C. Mondino" Neurological Institute, University of Pavia, Italy.
Address correspondence and reprint requests to Dr. Martino, Neuroimmunology Unit, DIBIT, San Raffaele Scientific Institute, via Olgettina 48, 20132 Milan, Italy; e-mail: martino.gianvito{at}hsr.it
The authors used a liquid-phase radiobinding assay to measure serum anti-myelin oligodendrocyte protein (MOG) immunoglobulin (Ig) G in 87 patients with multiple sclerosis (MS), in 12 patients with encephalomyelitis, and in 47 healthy subjects. Anti-MOG IgM was determined in samples obtained at onset from 40 of 87 patients with MS and in control subjects. The frequency of positive samples with low titers of anti-MOG IgG (
5.7%) and IgM (8.3%) was similar in all the groups and subgroups. Binding competition experiments showed that these antibodies had low affinity. Anti-MOG antibodies are not disease specific.
Received November 3, 2003. Accepted in final form February 2, 2004.
This article has been cited by other articles:
|
|
 |
|
  H Zephir, D Lefranc, S Dubucquoi, J de Seze, L Boron, L Prin, and P Vermersch Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 593 - 600. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Breithaupt, B. Schafer, H. Pellkofer, R. Huber, C. Linington, and U. Jacob Demyelinating Myelin Oligodendrocyte Glycoprotein-Specific Autoantibody Response Is Focused on One Dominant Conformational Epitope Region in Rodents J. Immunol., July 15, 2008; 181(2): 1255 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Amor and G. Giovannoni Antibodies to myelin oligodendrocyte glycoprotein as a biomarker in multiple sclerosis are we there yet? Multiple Sclerosis, November 1, 2007; 13(9): 1083 - 1085. [PDF]
|
|
|
|
 |
|
 J. Kuhle, C. Pohl, M. Mehling, G. Edan, M. S. Freedman, H.-P. Hartung, C. H. Polman, D. H. Miller, X. Montalban, F. Barkhof, et al. Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis N. Engl. J. Med., January 25, 2007; 356(4): 371 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pelayo, M. Tintore, X. Montalban, A. Rovira, C. Espejo, M. Reindl, and T. Berger Antimyelin Antibodies with No Progression to Multiple Sclerosis N. Engl. J. Med., January 25, 2007; 356(4): 426 - 428. [Full Text] [PDF]
|
|
|
|
|
|
S J Pittock, M Reindl, S Achenbach, T Berger, W Bruck, F Konig, Y Morales, H Lassmann, S Bryant, S B Moore, et al. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations Multiple Sclerosis, January 1, 2007; 13(1): 7 - 16. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Zhou, R. Srivastava, S. Nessler, V. Grummel, N. Sommer, W. Bruck, H.-P. Hartung, C. Stadelmann, and B. Hemmer Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis PNAS, December 12, 2006; 103(50): 19057 - 19062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C H Polman and J Killestein Anti-myelin antibodies in multiple sclerosis: clinically useful? J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 712 - 712. [Full Text] [PDF]
|
|
|
|
|
|
S Rauer, B Euler, M Reindl, and T Berger Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event. J. Neurol. Neurosurg. Psychiatry, June 1, 2006; 77(6): 739 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. Lalive, T. Menge, C. Delarasse, B. Della Gaspera, D. Pham-Dinh, P. Villoslada, H.-C. von Büdingen, and C. P. Genain Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis PNAS, February 14, 2006; 103(7): 2280 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Marta, A. R. Oliver, R. A. Sweet, S. E. Pfeiffer, and N. H. Ruddle Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology PNAS, September 27, 2005; 102(39): 13992 - 13997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. O'Connor, H. Appel, L. Bregoli, M. E. Call, I. Catz, J. A. Chan, N. H. Moore, K. G. Warren, S. J. Wong, D. A. Hafler, et al. Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein J. Immunol., August 1, 2005; 175(3): 1974 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lolli, B. Mulinacci, A. Carotenuto, B. Bonetti, G. Sabatino, B. Mazzanti, A. M. D'Ursi, E. Novellino, M. Pazzagli, L. Lovato, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis PNAS, July 19, 2005; 102(29): 10273 - 10278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 December 28 Highlight and Commentary Neurology, December 28, 2004; 63(12): 2201 - 2201. [Full Text] [PDF]
|
|
|
|
|
|
S. Gaertner, K. L. de Graaf, B. Greve, and R. Weissert Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis Neurology, December 28, 2004; 63(12): 2381 - 2383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Reder and J. J. Oger Anti-myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis Neurology, June 8, 2004; 62(11): 1922 - 1923. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
